Current Trends in Prostate Cancer Etiology, Pathogenesis and Diagnostics
By:
References
- Aumüller, G. (1979). Prostate Gland and Seminal Vesicles. Springer-Verlag, Berlin-Heidelberg. 380 pp.10.1007/978-3-642-67192-0
- Azmi, A. S., Bao, B., Sarkar, F. H. (2013). Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review. Cancer Metastasis Rev., 32 (3–4), 623–642.10.1007/s10555-013-9441-9384398823709120
- Bishayee, K., Khuda-Bukhsh, A. R. (2013). 5-lipoxygenase antagonist therapy: A new approach towards targeted cancer chemotherapy. Acta Biochim. Biophys. Sin. (Shanghai), 45 (9), 709–719.10.1093/abbs/gmt06423752617
- Brajtbord, J. S., Leapman, M. S., Cooperberg, M. R. (2017). The CAPRA score at 10 years: Contemporary perspectives and analysis of supporting studies. Eur. Urol., 71 (5), 705–709.10.1016/j.eururo.2016.08.06527616723
- Catalona, W. J., Partin, A. W., Sanda, M. G., Wei, J. T., Klee, G. G., Bangma, C. H., Slawin, K. M., Marks, L. S., Loeb, S., Broyles, D. L., et al. (2011). A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J. Urol., 185 (5),1650–1655.
- D’Amico, A. V., Whittington, R., Malkowicz, S. B. (2000). Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J. Clin. Oncol., 18 (6), 1164–1172.10.1200/JCO.2000.18.6.116410715284
- Del Re, M., Biasco, E., Crucitta, S., Derosa, L., Rofi, E., Orlandini, C., Miccoli, M., Galli, L., Falcone, A., Jenster, G. W. (2017). The detection of androgen receptor splice variant 7 in plasma derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur. Urol., 71, 680–687.10.1016/j.eururo.2016.08.01227733296
- Filella, X., Fernández-Galan, E., Fernández Bonifacio, R., Foj L. (2018). Emerging biomarkers in the diagnosis of prostate cancer. Pharmgenomics Pers. Med., 11, 83–94.10.2147/PGPM.S136026596164329844697
- Ghosh, J., Myers, C. E. (1998). Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A., 95 (22), 13182–13187.10.1073/pnas.95.22.13182237529789062
- Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P., Witte, O. N. (2010). Identification of a cell of origin for human prostate cancer. Science. 329 (5991), 568–571.
- Greene, E. R., Huang, S., Serhan, C. N., Panigrahy, D. (2011). Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat., 96 (1–4), 27–36.10.1016/j.prostaglandins.2011.08.004405134421864702
- Helgesen, F., Holmberg, L., Johansson, J. E. (1996). Trends in prostate cancer survival in Sweden, 1960 through 1988, evidence of increasing diagnosis of non-lethal tumours. J. Natl. Cancer Inst., 88 (17), 1216–1221.10.1093/jnci/88.17.12168780631
- Ingrosso, G., Detti, B., Scartoni, D., Lancia, A., Giacomelli, I., Baki, M., Carta, G., Livi, L., Santoni, R. (2018). Current therapeutic options in meta-static castration-resistant prostate cancer. Semin. Oncol., 45, 303–315.10.1053/j.seminoncol.2018.10.00130446166
- Jahn, J. L, Giovannucci, E. L., Stampfer, M. J. (2015). The high prevalence of undiagnosed prostate cancer at autopsy: Implications for epidemiology and treatment of prostate cancer in the prostate-specific antigen-era. Int. J. Cancer, 137 (12), 2795–2802.10.1002/ijc.29408448597725557753
- Kharaziha, P., Chioureas, D., Rutishauser, D., Baltatzis, G., Lennartsson, L., Fonseca, P., Azimi, A., Hultenby, K., Zubarev, R., Ullen, A. (2015). Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget, 6, 21740–21754.10.18632/oncotarget.3226467330025844599
- Kim, S. J., Kim, S. I. (2011). Current treatment strategies for castration-resistant prostate cancer. Korean J. Urol., 52, 157–165.10.4111/kju.2011.52.3.157306512621461278
- Kretschmer, A., Tilki, D. (2017). Biomarkers in prostate cancer: Current clinical utility and future perspectives. Crit. Rev. Oncol. Hematol., 120, 180–193.10.1016/j.critrevonc.2017.11.00729198331
- Leav, I., Plescia, J., Goel, H. L., Li, J., Jiang, Z., Cohen, R. J., Languino, L. R., Altieri, D. C. (2010). Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Amer. J. Pathol., 176 (1), 393–401.10.2353/ajpath.2010.090521279789919948822
- LSM.LV (2019). https://www.lsm.lv/raksts/zinas/latvija/visizplatitakais-veza-veids-viriesiem-prostatas-laundabigais-audzejs.a335221/ (accessed 10.08.2021) (in Latvian).
- Lu-Yao, G., Albertsen, P. C., Stamford, J. L. (2002). Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ, 325 (7367), 740.10.1136/bmj.325.7367.74012837312364300
- Moore, K., Dalley, A. (1999). Clinically Oriented Anatomy. Lippincott Williams & Wilkins, Baltimore, Maryland. 1163 pp.
- Mottet, N., Cornford, P., van den Bergh, R. C. N., De Santis, M., Fanti, S., Gillessen, S., Grummet, J., Henry, A. M., Lam, T. B., Mason, M. D., van der Kwast, T. H., van der Poel, H. G., Rouviere, O., Schoots, I. G., Tilki, D., Wiegel, T. (2020). Oncology Guidelines, Prostate Cancer. https://uroweb.org/guideline/prostate-cancer/ (accessed 10.08.2021).
- Narizhneva, N. V., Tararova, N. D., Ryabokon, P., Shyshynova, I., Prokvolit, A., Komarov, P. G., Purmal, A. A., Gudkov, A. V., Gurova, K. V. (2009). Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. Cell Cycle, 8 (24), 4155–4167.10.4161/cc.8.24.10316289689519946220
- Reedy, G. M., Cance, W. G., Kim, K., Lacasse, L., Phillips, T., Reicin, K. (2020). About Prostate Cancer. American Cancer Society.
- Rosenberg, J. E. (2005). Scientists discover anti-cancer mechanism that arrests early prostate cancer. Science Daily, 4 August. https://www.sciencedaily.com/releases/2005/08/050804074959.htm (accessed 10.08.2021).
- Schmelz, H. U., Sparwasser C., Weidner, W. (2006). Facharztwissen Urologie, Differenzierte Diagnostik und Therapie. Springer Medizin Verlag, Heidelberg. 736 S.
- Senapati, S., Rachagani, S., Chaudhary, K., Johansson, S. L., Singh, R. K., Batra, S. K. (2010). Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK–RhoA signaling pathway. Oncogene. 29 (9), 1293–1302.10.1038/onc.2009.420289681719946339
- Siegel, R. L., Miller, K. D., Jemal, A. (2019). Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34.10.3322/caac.2155130620402
- Soekmadji, C., Russell, P. J., Nelson, C. C. (2013). Exosomes in prostate cancer: Putting together the pieces of a puzzle. Cancers (Basel), 5 (4), 1522–1544.10.3390/cancers5041522
- Stieve, H. (1930). Männliche Genitalorgane. In: Handbuch der mikroskopischen Anatomie des Menschen. Vol. VII Part 2. Springer, Berlin.
- Strom, P., Kartasalo, K., Olsson, H., Solorzano, L., Delahunt, B., Berney, D. M., Bostwick, D. G., Evans, A. J., Grignon, D. J., Humphrey, P. A. et al. (2020). Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. Lancet Oncol., 21 (2), 222–232.10.1016/S1470-2045(19)30738-7
- Tarhan, F., Orcun, A., Kucukercan, I., Camursoy, N., Kuyumcuoglu, U. (2005). Effect of prostatic massage on serum complexed prostate-specific antigen levels. Urology, 66,1234–1238.10.1016/j.urology.2005.06.07716360449
- Thompson, I. M. (2006). PSA: A biomarker for disease. A biomarker for clinical trials. How useful is it? J. Nutr., 136, 2704S.
- van der Pol, E., Böing, A. N., Harrison, P., Sturk, A., Nieuwland, R. (2012). Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol. Rev., 64 (3), 676–705.10.1124/pr.112.00598322722893
- Van Leenders, G. J. L. H., van der Kwast, T. H., Grignon, D. J., Evans, A. J., Kristiansen, G., Kweldam, C. F., Litjens, G., McKenney, J. K., Melamed, J., Mottet, N., et al. (2020). The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Amer. J. Surg. Pathol., 44 (8), e87–e99.10.1097/PAS.0000000000001497738253332459716
- Watanabe, S. I., Miyata, Y., Kanda, S., Iwata, T., Hayashi, T., Kanetake, H., Sakai, H. (2009). Expression of X-linked inhibitor of apoptosis protein in human prostate cancer specimens with and without neo-adjuvant hormonal therapy. J. Cancer Res. Clin. Oncol., 136 (5), 787–793.
- Yao, V., Berkman, C. E., Choi, J. K., O’Keefe, D. S., Bacich, D. J. (2010). Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate, 70 (3), 305–316.10.1002/pros.2106519830782
- Zha, J., Huang, Y. F. (2009). TGF-beta/Smad in prostate cancer: An update. Zhonghua Nan Ke Xue (in Chinese), 15 (9), 840–843.
Language: English
Page range: 319 - 327
Submitted on: Jan 12, 2021
Accepted on: Apr 26, 2021
Published on: Nov 15, 2021
Published by: Latvian Academy of Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year
Keywords:
Related subjects:
© 2021 Kristofs Folkmanis, Elizabete Junk, Evelīna Merdane, Inese Folkmane, Valdis Folkmanis, Sergejs Isajevs, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.